Nivolumab/Chemotherapy Generate Survival Benefit Vs Chemotherapy Alone in Gastric Cancer, Regardless of TMB
April 11th 2022
The combination of nivolumab with chemotherapy elicited a higher overall survival rate compared with chemotherapy alone in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, regardless of tumor mutational burden (TMB) status.